Artielle ImmunoTherapeutics
San Mateo · Founded 2004
About Artielle ImmunoTherapeutics
Artielle ImmunoTherapeutics, Inc., a biopharmaceutical company, develops recombinant T-cell receptor ligands (RTLs) to treat T-cell mediated inflammatory diseases. It develops RTL1000, a compound for the treatment of multiple sclerosis. The company focuses on the development of therapeutics for the treatment of autoimmune diseases that include multiple sclerosis, celiac disease, type 1 diabetes, rheumatoid arthritis, uveitis, stroke, optic neuritis, and other diseases. Artielle ImmunoTherapeutics, Inc. was founded in 2004 and is based in Tigard, Oregon.
Company Facts
- Founded: 2004
- Legal name: Artielle ImmunoTherapeutics Inc
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $11.2M
- Funding stage: Early Stage Venture
- Last round: Convertible Note (Apr 2010)
- Website: artielle.com
- Phone: (650) 401-2000
Social Profiles
Canonical: https://fsome.com/organization/artielle-immunotherapeutics-8464513 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.